Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum
Reports on the therapeutic drug monitoring (TDM) of second- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer patients are limited and are required to improve the safety of EGFR-TKI therapy. Some EGFR-TKIs have active metabolit...
Main Authors: | Chishima, H. (Author), Hakamata, J. (Author), Ikemura, S. (Author), Ishikawa, E. (Author), Jibiki, A. (Author), Kawazoe, H. (Author), Kimura, M. (Author), Kuniyoshi, O. (Author), Muramatsu, H. (Author), Nakada, H. (Author), Nakajima, H. (Author), Nakamura, T. (Author), Nakaya, N. (Author), Sato, I. (Author), Suehiro, N. (Author), Suzuki, S. (Author), Yokoyama, Y. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier B.V.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01) -
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
by: Lee CS, et al.
Published: (2021-08-01) -
Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01) -
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01) -
Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)